How much funding has InterVenn raised?

InterVenn has raised $244.4M in total funding, most recently a Series C round.

Who are InterVenn's investors?

InterVenn's investors include Genoa Ventures, Anzu Partners, SoftBank, Amplify Partners, True Ventures, Heritage Provider Network.

Where is InterVenn headquartered?

InterVenn is headquartered in South San Francisco, California, United States.

What industry is InterVenn in?

InterVenn operates in Artificial Intelligence, Biotech, Healthcare.

How many employees does InterVenn have?

InterVenn has 51-200 employees.

InterVenn

InterVenn Biosciences | Clinical Glycoproteomics

South San Francisco, United States · Founded 2017 · $244.4M raised

Artificial Intelligence

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2017
Business Model: B2B

Website: intervenn.bio
Total Funding: $244.4M
Last Round: $201.0M Series CAug 2021
Rounds: 3

About

InterVenn Biosciences pioneers AI- and ML-powered glycoproteomic analysis through its GlycoVision platform, enabling high-throughput biomarker discovery from blood samples. Co-founded in 2017 by Nobel Laureate Carolyn Bertozzi, Dr. Carlito Lebrilla, and Aldo Carrascoso, the company serves biopharma partners and clinicians with diagnostic applications including GlycoKnow Ovarian for ovarian cancer detection.

Summary

InterVenn is an Artificial Intelligence company based in South San Francisco, United States, founded in 2017. It has raised $244.4M in total across 3 rounds, most recently a $201.0M Series C round in Aug 2021. Investors include Genoa Ventures, Anzu Partners and SoftBank.

LinkedIn X (Twitter)